Medical Science and Public Health

Researchers at University Hospitals Cleveland Medical Center report in Cell Reports Medicine that restoring levels of the cellular energy molecule NAD+ in Alzheimer’s mouse models using an experimental drug reversed amyloid and tau buildup and fully restored cognitive function, while also normalizing a key blood biomarker (phosphorylated tau 217). The team, led by Dr. Andrew A. Pieper, also found severe NAD+ depletion in both Alzheimer’s mice and human Alzheimer’s brain tissue, suggesting that correcting NAD+ imbalance could be a potential therapeutic strategy, though the authors caution the findings are from animals and may not directly translate to humans.